Browsing ICR Divisions by title
Now showing items 3681-3700 of 4595
-
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
(NATURE PORTFOLIO, 2024-01-01)In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant ... -
The role of cancer-associated fibroblasts in altering signal transduction and drug resistance in KRAS mutated cancers
(Institute of Cancer Research (University Of London), 2023-01-04)KRAS is commonly mutated in solid tumours but effective treatment is limited due to resistance. Cancer-associated fibroblasts (CAFs) are a key tumour microenvironment component but how it interacts with KRAS mutant-cancer ... -
The role of the radiation therapy breast boost in the 2020s.
(CHURCHILL LIVINGSTONE, 2023-03-17)Given that most local relapses of breast cancer occur proximal to the original location of the primary, the delivery of additional radiation dose to breast tissue that contained the original primary cancer (known as a ... -
Role of the Tripartite Motif Protein 27 in Cancer Development
(OXFORD UNIV PRESS INC, 2012-06-01)Background The tripartite motif family protein 27 (TRIM27) is a transcriptional repressor that interacts with, and attenuates senescence induction by, the retinoblastoma-associated protein (RB1). High expression of TRIM27 ... -
Roles of cancer associated fibroblasts in squamous cell carcinoma
(Institute of Cancer Research (University Of London), 2021-03-31)Cancer associated fibroblasts (CAFs) play a key role in the tumour microenvironment (TME) of squamous cell carcinoma. Influenced by cues from cancer cells, CAFS remodel the extracellular matrix and secrete cytokines and ... -
Roles of Elongator Dependent tRNA Modification Pathways in Neurodegeneration and Cancer.
(MDPI, 2018-12-28)Transfer RNA (tRNA) is subject to a multitude of posttranscriptional modifications which can profoundly impact its functionality as the essential adaptor molecule in messenger RNA (mRNA) translation. Therefore, dynamic ... -
RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.
(AMER ASSOC CANCER RESEARCH, 2017-03-01)Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor ... -
ROS Dynamics Delineate Functional States of Hippocampal Neural Stem Cells and Link to Their Activity-Dependent Exit from Quiescence.
(CELL PRESS, 2021-02-04)Cellular redox states regulate the balance between stem cell maintenance and activation. Increased levels of intracellular reactive oxygen species (ROS) are linked to proliferation and lineage specification. In contrast ... -
RPAP3 provides a flexible scaffold for coupling HSP90 to the human R2TP co-chaperone complex.
(Springer Science and Business Media LLC, 2018-04-16)The R2TP/Prefoldin-like co-chaperone, in concert with HSP90, facilitates assembly and cellular stability of RNA polymerase II, and complexes of PI3-kinase-like kinases such as mTOR. However, the mechanism by which this ... -
rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
(NATURE PORTFOLIO, 2016-11-15)NBS1, also known as NBN, plays an important role in maintaining genomic stability. Interestingly, rs2735383 G > C, located in a microRNA binding site in the 3'-untranslated region (UTR) of NBS1, was shown to be associated ... -
RTT-led IGRT for cervix cancer; training, implementation and validation.
(Elsevier BV, 2019-12-16)INTRODUCTION: IGRT in cervical cancer treatment delivery is complex due to significant target and organs at risk (OAR) motion. Implementing image assessment of soft-tissue target and OAR position to improve accuracy is ... -
Runs of homozygosity and testicular cancer risk.
(WILEY, 2019-07-01)BACKGROUND: Testicular germ cell tumour (TGCT) is highly heritable but > 50% of the genetic risk remains unexplained. Epidemiological observation of greater relative risk to brothers of men with TGCT compared to sons has ... -
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-07-01)PURPOSE: Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. ... -
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
(NATURE PORTFOLIO, 2023-07-25)All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose ... -
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-08-01)PURPOSE: Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety and ... -
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
(ELSEVIER, 2023-04-01)BACKGROUND: Although introduction of immune checkpoint inhibitors has revolutionized the treatment of cancer, their response rates are generally low. Preclinical and early phase clinical data suggest that MEK inhibition ... -
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
(2021-11-19)Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune ... -
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
(2019-08-13)Background PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between ... -
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
(AMER SOC HEMATOLOGY, 2016-07-28)Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ...